|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 68:7–30. 2016. View Article : Google Scholar
|
|
2
|
Subramanian J, Regenbogen T, Nagaraj G,
Lane A, Devarakonda S, Zhou G and Govindan R: Review of ongoing
clinical trials in non-small-cell lung cancer: A status report for
2012 from the clinicaltrials.gov web site. J Thorac Oncol.
8:860–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hodkinson PH, MacKinnon A and Sethi T:
Targeting growth factors in lung cancer. Chest. 133:1209–1216.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Muñoz M and Coveñas R: Involvement of
substance P and the NK-1 receptor in cancer progression. Peptides.
48:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Muñoz M, González-Ortega A, Rosso M,
Robles-Frías MJ, Carranza A, Salinas-Martín MV and Coveñas R: The
substance P/neurokinin-1 receptor system in lung cancer: Focus on
the antitumor action of neurokinin-1 receptor antagonists.
Peptides. 38:318–325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Muñoz M, Rosso M and Coveñas R:
Neurokinin-1 receptor antagonists in lung cancer therapy. Lett Drug
Des Discov. 14:1465–1476. 2017. View Article : Google Scholar
|
|
7
|
Kramer MS, Cutler N, Feighner J,
Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D,
Wyatt-Knowles E, et al: Distinct mechanism for antidepressant
activity by blockade of central substance P receptors. Science.
281:1640–1645. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tebas P, Tuluc F, Barrett JS, Wagner W,
Kim D, Zhao H, Gonin R, Korelitz J and Douglas SD: A randomized,
placebo controlled, double masked phase IB study evaluating the
safety and antiviral activity of aprepitant, a neurokinin-1
receptor antagonist in HIV-1 infected adults. PLoS One.
6:e241802011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Muñoz M and Coveñas R: Safety of
neurokinin-1 receptor antagonists. Expert Opin Drugs Safety.
12:673–685. 2013. View Article : Google Scholar
|
|
10
|
Muñoz M, Pérez A, Coveñas R, Rosso M and
Castro E: Antitumoural action of L-733,060 on neuroblastoma and
glioma cell lines. Arch Ital Biol. 142:105–112. 2004.PubMed/NCBI
|
|
11
|
Muñoz M, Rosso M, Pérez A, Coveñas R,
Rosso R, Zamarriego C and Piruat JI: The NK1 receptor is involved
in the antitumoural action of L-733,060 and in the mitogenic action
of substance P on neuroblastoma and glioma cell lines.
Neuropeptides. 39:427–432. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu H, Boyle TA, Zhou C, Rimm DL and Hirsch
FR: PD-L1 Expression in lung cancer. J Thorac Oncol. 11:964–975.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee M, McCloskey M and Staples S:
Prolonged use of aprepitant in metastatic breast cancer and a
reduction in CA153 tumour marker levels. Int J Cancer Clin Res.
3:0712016. View Article : Google Scholar
|
|
14
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Medrano S, Gruenstein E and Dimlich RV:
Substance P receptors on human astro-cytoma cells are linked to
glycogen breakdown. Neurosci Lett. 167:14–18. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alfieri AB and Cubeddu LX: Efectos de los
antagonistas de los receptores NK1 y de la dexametasona sobre la
inflamación neurogénica inducida por ciclofosfamida y por radiación
X, en la rata. Archivos Venezolanos de Farmacologia y Terapeutica.
23:61–66. 2004.
|
|
17
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ,
Dobelbower M, et al: Non-small cell lung cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
